Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; UNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology & Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Inhalon Biopharma, Research Triangle Park, NC 27707, USA.
Inhalon Biopharma, Research Triangle Park, NC 27707, USA.
J Control Release. 2021 Jan 10;329:87-95. doi: 10.1016/j.jconrel.2020.11.057. Epub 2020 Dec 1.
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.
COVID-19，即由 SARS-CoV-2 感染引起的疾病，需要紧急开发治疗干预措施。由于单克隆抗体（mAbs）具有安全性、特异性和快速进入临床的潜力，因此它们是一种极具前景的抗病毒或抗炎药物。在此，我们通过分析先前为其他急性呼吸道感染（ARIs）推进抗病毒 mAbs 的努力，强调了基于 mAb 的免疫疗法在 COVID-19 中面临的挑战。我们提供了证据支持通过使用振动网孔式雾化器进行吸入式给药的 mAbs 在阳性诊断后立即进行早期干预，这是治疗 COVID-19 的一种很有前途的方法。
